-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
2021-2022 Family Shelf Medicine List: Which baby is on the list this year!
Author: meilin
is located at: Health Encyclopedia
is located at: Health Encyclopedia
On September 19th, the award ceremony of "2021-2022 China Family Standing Health Products Listed Brands (Chinese Family Regular Medicine Listed Brands/Chinese Family Standing Health Food Listed Brands)" jointly sponsored by Family Doctor Online and the New Generation Market Monitoring Agency was successfully held
in Shanghai.
Since the launch of the selection activity on June 28, after several major stages such as online declaration, qualification review, market research, popularity praise, and social publicity, the two honorary lists
of "2021-2022 China Family Standing Medicine Listed Brands" and "2021-2022 Chinese Family Standing Health Food Listed Brands" were finally released.
Among them, a total of 93 products in 24 categories of standing medicines have been successfully listed
.
After Merck introduced the original drug to China in 1995, it has helped many diabetics improve their diseases and embrace healthy lives, and is also actively and continuously carrying out a series of clinical studies on metformin for Chinese diabetic patients, which has promoted the development
of diabetes in China.
Merck will continue to explore new ways to raise awareness, prevention and management of disease protection in the future, and benefit more diabetics through high-quality and affordable drugs and an excellent product portfolio, so as to help realize the vision
of "improving the lives of 40 million patients in China by 2025".